undamentalytics Newsletter
Sign in

Lyell Immunopharma, Inc. balance sheet

At the end of fiscal 2025, Lyell Immunopharma, Inc. had total assets of $340m, total liabilities of $91.8m and shareholders' equity of $248m. It held $60.2m in cash against $0 of debt: net cash of $60.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents971402941241461066073
Total current assets—618626651555380261214
Total assets—9081,127938750491340311
Accounts payable—9345534
Deferred revenue (current)—650————
Total current liabilities—49473735544940
Total debt00000000
Total liabilities—190198104951089277
Shareholders' equity−111−293930833655383248234
Non-controlling interests and other (assets − liabilities − equity)—1,011——————
Net debt (negative = net cash)−97−140−294−124−146−106−60−73
Shares outstanding—————15m21m23m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AIM vs LYELIBIO vs LYELLSTA vs LYEL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lyell Immunopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lyell Immunopharma, Inc.